AVBP Q3 2023 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$17M

Net Income

-$14M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$217,000

Balance Sheet

Total Assets

$182M

Total Liabilities

$10M

Stockholders' Equity

$172M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$17M	-$12M	-42.0%
Net Income	-$14M	-$12M	-22.4%